Department of Basic Oncology, Hacettepe University Cancer Institute, 06230, Ankara, Turkey.
Department of Immunology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey.
Cancer Immunol Immunother. 2021 Jan;70(1):75-87. doi: 10.1007/s00262-020-02656-y. Epub 2020 Jul 6.
Myeloid-derived suppressor cells (MDSC) populate the peripheral blood and contribute to immune regulation in cancer. However, there is limited knowledge on the myeloid cell types with proinflammatory capacities that may serve as opponents of MDSC. In the circulation of cancer patients, a monocyte subpopulation was identified with a specific immunophenotype and transcriptomic signature. They were predominantly CD14CD33CD16HLA-DR cells that typically expressed CD66b. In accordance with the transcriptomics data, NALP3, LOX-1 and PAI-1 levels were also significantly upregulated. The CD66b monocytes displayed high phagocytic activity, matrix adhesion and migration, and provided costimulation for T cell proliferation and IFN-γ secretion; thus, they did not suppress T cell responses. Irrespective of clinical stage, they were identified in various cancers. In conclusion, the CD66b monocytes represent a novel myeloid subpopulation which is devoid of immune regulatory influences of cancer and displays enhanced proinflammatory capacities.
髓系来源的抑制细胞（MDSC）存在于外周血中，并参与癌症的免疫调节。然而，对于具有促炎能力的髓系细胞类型，我们知之甚少，这些细胞可能是 MDSC 的拮抗物。在癌症患者的循环中，鉴定出一种具有特定免疫表型和转录组特征的单核细胞亚群。它们主要是 CD14CD33CD16HLA-DR 细胞，通常表达 CD66b。根据转录组学数据，NALP3、LOX-1 和 PAI-1 的水平也显著上调。CD66b 单核细胞表现出高吞噬活性、基质黏附和迁移，并为 T 细胞增殖和 IFN-γ 分泌提供共刺激作用；因此，它们不会抑制 T 细胞反应。无论临床分期如何，它们都存在于各种癌症中。总之，CD66b 单核细胞代表了一种新型的髓系亚群，它没有癌症的免疫调节影响，并显示出增强的促炎能力。
